Posts tagged insulin
Leerink downgrades Adocia to market perform

Leerink downgraded Adocia (NXT PA:ADOC.FP) to “market perform” and slashed its price target to €15.00 from €82.00 after Eli Lilly terminated its collaboration for Adocia’s ultra-fast insulin product, BioChaperone Lispro.

Read More
BTIG starts Intra-Cellular Therapies at buy

BTIG launched coverage of Cellular Therapies (NASDAQ:ITCI) with a “buy” rating and $44 price target, saying there is considerable promise for the company’s antipsychotic, ITI-007, in multiple indications. The stock closed at $15.05 on Dec. 21.

Read More
Oramed GLP-1 analog found safe in study

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients.

Read More
Oramed gets additional milestone from HTIT

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China.

The milestone is part of a license and investment agreement between Oramed and HTIT, and follows Oramed’s report of additional positive efficacy and safety data from a recently completed Phase 2b trial of its oral insulin product, ORMD-0801.

Read More
Tandem expands pediatric indication of insulin pump

Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older.

The t:slim Pump is the first and only touchscreen insulin pump cleared by the FDA. The expanded pediatric indication applies to the current t:slim pump features, with no changes to the existing user interface.

Read More
Oramed receives patent in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations of Proteins” by the State Intellectual Property Office of the People’s Republic of China.

The patent addresses Oramed’s platform technology, which underlies its products, including ORMD-0801, an orally ingestible insulin capsule.

Read More